In a previous issue of Critical Care, Lehmann and colleagues analyzed the potential impact of a commercially available PCR-based diagnostic method to test the whole blood of septic patients for bacterial DNAemia [1]. Th e evidence they collected is derived from their previous prospective observational trial showing reduction of inadequate treatment days [2] coupled with two other unrelated studies on outcomes [3,4]. Th e authors then developed a mathematical model to suggest that PCR-based detection of pathogens early during sepsis might reveal cost-eff ective, under-defi ned conditions. Th is is clearly a landmark paper in molecular microbial diagnostics but its predictions derive from numerous assumptions and therefore warrant a careful interpre tation.
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It is now obvious that adequate empiric therapy must be administered as soon as possible to septic patients in order to reduce mortality [5] . An early switch, however, from an empiric regimen initiated on clinical clues to an adapted therapy based on a probabilistic antimicrobial susceptibility, itself derived from the organism identification, might lead to more targeted and more appropriate therapy. Th is implies broadening the antimicrobial spectrum for an unexpected organism and/or narrowing the empiric coverage (for example, by stopping glycopeptides if an Escherichia coli strain is detected). Benefi ts might therefore derive from an improved clinical outcome and/or from savings due to drug adjustments. Th is strategy could also, however, lead to higher costs due to molecular diagnostics and adjusted therapy. And here comes the challenge to design such a healtheconomic study: one needs to bridge several medical disciplines (intensive medicine, laboratory medicine, epidemiology and infectious disease special ists, and so forth) to provide the full cost picture. Th is picture is needed to convince our hospital directors to implement costly but benefi cial approaches, by showing them strong data supporting a paradigm shift in clinical microbiology.
Lehmann and colleagues have partially overcome these hurdles by compiling data from diff erent studies [1] . Importantly, their approach makes several major assumptions: molecular testing does not provide false positive results (negative results are not considered here -hence, the issue of suboptimal detection sensitivity and the limited microbial diversity detection of the assay are not relevant here); the assay is performed only once, as soon as possible; results are rapidly delivered 24 hours per day to the physician in charge, who will immediately and optimally adjust therapy; the prevalence of positive blood cultures should be high (here more than 15%, as observed in the emergency room wards and hence mostly detecting community-acquired infections); and, fi nally, there should be a high proportion of inadequate empirical treat ments (here more than 25%, which might be true mostly for hospital-acquired infections and therefore in wards other than the emergency room). Th e applicability of this approach is thus highly contextual as a function of the local epidemiology, of the respect of antimicrobial prescription guidelines, and assuming ideal 24 hours per day laboratory support. Th e cost-effi ciency model should therefore be assessed by each potential user, for its intended target patient population and wards, by using its own numbers.
Finally, the compilation of data contains the risk that false positive PCR results (for example, the unexpected detection of DNA from Pseudomonas aeruginosa or yeasts/fungi) might overestimate the rate of inadequate antimicrobial therapy and inadequately support clinically-irrelevant, expensive and perhaps dangerous medical decisions. Th ese limitations will have to be addressed in carefully designed studies.
In the future, such studies will have to confi rm that the rapid availability of such PCR assays -a true logistical challenge to most diagnostic laboratories -can indeed be followed by changes in therapy and could prove costeff ective, across diff erent wards, hospitals and countries. Once validated, such molecular assays will probably be bundled with computer-assisted antimicrobial prescription and electronic reporting tools.
Abbreviations PCR, polymerase chain reaction.
